Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology out of the University of Michigan, the Company’s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. We have built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.
Founded in 2010, Ascentage Pharma is headquartered in Suzhou, China, with R&D and cGMP manufacturing facilities in Suzhou, Shanghai and Taizhou, and offices in the U.S. We have more than 190 employees, including 150 world-class scientific researchers and clinicians, and our founding leadership team has been pioneering apoptosis-targeted drug innovation for more than two decades. With our proprietary design platform, robust product pipeline, and commitment to excellence, we believe our Company is well positioned to deliver first- and best-in-class therapies that can transform the lives of patients around the world.